Home » Editor's Viewpoint » Editor’s Viewpoint – Not All Doom And Gloom In The Care Industry

Editor’s Viewpoint – Not All Doom And Gloom In The Care Industry

Peter Adams, Editor of The Carer

Peter Adams, Editor of The Carer

One of the great delights of my job editing The Carer is the number of ‘feelgood’ stories we get from our readership; from events, awards, birthdays, weddings, anniversaries, themed days and openings, we are very grateful to you for sending them to us and please continue. We are delighted to include them on our website and in our publication!

We do, rather unfortunately, live in times where negative and salacious stories often hit the headlines. The care industry is often an easy target, with documentaries and news stories often exposing the negative, no matter how rare those negatives are. They almost never report the good news and the wonderful work that people in the industry do. So, as I say, if mainstream media is not prepared to highlight the positive, we will!

I read a rather interesting article which is on our website regarding acupuncture and Alzheimer’s disease. Whilst the study appears to be only at a very early stage, and very limited, the article states; “A review of existing evidence suggests that acupuncture may be linked to benefits for people with early memory and thinking problems”.

Looking into this a little further, it would appear there are insufficient trials available on which to base any conclusions.

I occasionally have acupuncture treatment for arthritis, and although I don’t get a great deal of benefit, I do have a reduction in pain after treatment, and I am that little more mobile!

So I tend not to discount complimentary medicine and one of those people who likes to think that I am open-minded, but would be very interested if any readers have any experience of use to share!

Peter Adams
Editor of The Carer


Check Also


Alzheimer’s Drug Trial Targets By-Product Of Gum Disease

In a poster presented at the Alzheimer’s Association International Conference earlier this week researchers provided an overview of the development of the drug, known as COR388, and how they are working to test its ability to slow the progression of Alzheimer’s symptoms. The researchers highlighted previous findings from a small, ...